Changjiang Life Science Technology (00775.HK) announced its interim performance, with a loss attributable to shareholders of HKD 28.73 million, a year-on-year decrease of 80.95%.

Zhitong Finance APP news, Changjiang Life Science Technology (00775.HK) announced its interim results for 2026, reporting revenue of HKD 2.716 billion, an increase of 4.22% year-on-year; the company's attributable loss to shareholders was HKD 28.73 million, a decrease of 80.95% year-on-year; loss per share was HKD 0.003.